Amendments to the Claims

This listing replaces all prior versions and listings of claims in the application.

Listing of Claims

1. (Original) A formulation comprising at least one hybridoma having at least one first cell fused to at least one second cell; wherein said first cell is an antigen presenting cell selected from the group consisting of a macrophage and a dendritic cell, and said second cell is selected from the group consisting of a tumor cell and a virally infected cell.

2. (Original) The formulation of Claim 1, wherein said dendritic cells are selected from the group consisting of cutaneous epidermal Langerhans cells, dermal dendritic cells, lymph node dendritic cells, spleen dendritic cells and dendritic cells derived through *in vitro* culture of precursors.

3. (Original) The formulation of Claim 1, wherein said tumor cells are selected from the group consisting of melanoma cells, lung carcinoma cells, sarcomas, prostate carcinoma cells, breast carcinoma cells, colon carcinoma cells and cervical carcinoma cells.

4. (Original) The formulation of Claim 1, wherein said virally infected cells are selected from the group consisting of cells infected with influenza virus, human immunodeficiency virus, cytomegalo virus, human papilloma virus and herpes simplex virus.

5. (Original) The formulation of Claim 1, wherein said hybridoma contains a ratio of first cells to second cells between about 1:100 and 100:1.

6. (Original) The formulation of Claim 1, wherein said hybridoma contains a ratio of first cells to second cells of between about 1:10 and 10:1.

7. (Original) The formulation of Claim 1, wherein said hybridoma contains a ratio of first cells to second cells of about 6:1.

8. (Original) A pharmaceutical composition comprising:

at least one hybridoma, and

a suitable pharmaceutical carrier;

wherein each hybridoma is comprised of at least one first cell fused to at least one second cell;

wherein said first cell is an antigen presenting cell selected from the group consisting of a macrophage and a dendritic cell, and said second cell is selected from the group consisting of a tumor cell and a virally infected cell.

9. (Original) The pharmaceutical composition of Claim 8, wherein said suitable pharmaceutical carrier is selected from the group consisting of saline and phosphate buffered saline.

10. (Original) The pharmaceutical composition of Claim 8, wherein said hybridomas have a ratio of first cells to second cells of between about 1:100 and 100:1.

11. (Original) The pharmaceutical composition of Claim 8, wherein said hybridomas have a ratio of first cells to second cells of between about 1:10 and 10:1.

12. (Original) The pharmaceutical composition of Claim 9, wherein said hybridomas have a ratio of first cells to second cells of about 6:1.

13-36. (Canceled)

37. (New) The formulation of Claim 1, wherein the second cell is a tumor cell.

38. (New) The formulation of Claim 1, wherein the second cell is a virally infected cell.

39. (New) The pharmaceutical composition of Claim 8, wherein the second cell is a tumor cell.

40. (New) The formulation of Claim 8, wherein the second cell is a virally infected cell.